Atypical IgM multiple myeloma with deletion of c-MAF

被引:0
|
作者
Juarez Salcedo, L. M. [1 ]
Lopez Rubio, M. [1 ]
Gil Fernandez, J. J. [1 ]
Garcia-Suarez, J. [1 ]
Magro, E. [1 ]
Arranz, E. [2 ]
Gutierrez Jomarron, I. [1 ]
Marcellini Antonio, S. [1 ]
Blasco, A. [3 ]
Burgaleta, C. [1 ,4 ]
机构
[1] Hosp Univ Principe Asturias, Div Hematol, Alcala De Henares, Spain
[2] Hosp Univ Princesa, Cytogenet Div, Alcala De Henares, Spain
[3] Hosp Univ Principe Asturias, Div Anat Pathol, Madrid, Spain
[4] Univ Alcala Henares, Dept Med, Madrid, Spain
关键词
Multiple myeloma; Waldenstrom's macroglobulinemia; C-MAF; T(11/14)(Q13; Q32); TRANSLOCATION; SPECTRUM; ENTITY; RARE;
D O I
10.1111/ijlh.12385
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IgM multiple myeloma (MM) is a rare subtype of myeloma that shares clinical and pathological features with Waldenstrom's macroglobulinaemia. These are two separate entities that differ both in therapy and prognosis. We report a 57-year-old male, who presented with anaemia, hypercalcaemia, acute renal failure and several vertebral fractures that clinically suggested a multiple myeloma. Further investigations revealed a serum monoclonal component of IgM lambda type and a bone marrow infiltrated by small, lymphoplasmocytic cells. IgM MM was finally diagnosed by means of both inmunophenotypic and immunohistochemistry techniques, stressing the importance of inmunophenotypic evaluation when clinical and morphological features are discordant. Fluorescence in situ hybridization (FISH) studies disclosed a particular combination of deletion 13q14, t(11;14) and monoallelic deletion C-MAF without t(14; 16). The clinical evolution after a Bortezomib-containing polychemotherapy and autologous stem cell transplantation (ASCT) conditioned with busulphan and melphalan is also presented. This very uncommon case highlights the impact of immunophenotyping on the differential diagnosis between IgM MM and WM, to choose the best treatment and establish an appropriate outcome.
引用
收藏
页码:686 / 689
页数:4
相关论文
共 50 条
  • [2] c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma
    Chang, Hong
    Qi, Q.
    Xu, W.
    Patterson, B.
    LEUKEMIA, 2007, 21 (07) : 1572 - 1574
  • [3] c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma
    Hong Chang
    Q Qi
    W Xu
    B Patterson
    Leukemia, 2007, 21 : 1572 - 1574
  • [4] c-maf oncogene dysregulation in multiple myeloma: Frequency and biological relevance
    Rasmussen, T
    Knudsen, LM
    Dahl, IMS
    Johnsen, HE
    LEUKEMIA & LYMPHOMA, 2003, 44 (10) : 1761 - 1766
  • [5] Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma
    Jiang, Qiuyun
    Mao, Hongwu
    He, Guisong
    Mao, Xinliang
    CANCER LETTERS, 2022, 543
  • [6] GSK3 mediated c-Maf phosphorylation in multiple myeloma
    Herath, Nirmitha
    Rocques, Nathalie
    Eychene, Alain
    Pouponnot, Celio
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S50 - S50
  • [7] Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma
    Xu, Yujia
    Xu, Min
    Tong, Jiefei
    Tang, Xiaowen
    Chen, Jinhao
    Chen, Xuehan
    Zhang, Zubin
    Cao, Biyin
    Stewart, A. Keith
    Moran, Michael F.
    Wu, Depei
    Mao, Xinliang
    BLOOD, 2021, 137 (11) : 1478 - 1490
  • [8] c-maf in multiple myeloma:: An oncogene enhancing tumor-stroma interactions
    Kienast, J
    Berdel, WE
    CANCER CELL, 2004, 5 (02) : 109 - 110
  • [9] Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
    GuoQing Wei
    LiJun Wang
    HanJin Yang
    XiaoYan Han
    GaoFeng Zheng
    WeiYan Zheng
    Jie Sun
    JiMin Shi
    WenJun Wu
    Yi Zhao
    DongHua He
    Bo Wang
    Zhen Cai
    JingSong He
    Experimental Hematology & Oncology, 6
  • [10] Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
    Wei, GuoQing
    Wang, LiJun
    Yang, HanJin
    Han, XiaoYan
    Zheng, GaoFeng
    Zheng, WeiYan
    Sun, Jie
    Shi, JiMin
    Wu, WenJun
    Zhao, Yi
    He, DongHua
    Wang, Bo
    Cai, Zhen
    He, JingSong
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6